The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.
Upcoming data could help Novartis broaden the reach of its heart failure drug Entresto, while Miragen awaits a key test of its microRNA approach.
Both Ardelyx and Rhythm Pharmaceuticals are looking for phase III clinical wins to kick off filing discussions for pipeline leads.
As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.
Lilly is still trying to find a therapeutic window following gastrointestinal issues with its brightest pipeline hope, the GIP/GLP1 agonist tirzepatide.
Continued interest in the Sting pathway might come as a surprise, though secrecy suggests that asset prices are failing.
A delayed decision on Karyopharm’s selinexor is the pick of the bunch for July.
Bristol-Myers Squibb’s $74bn bid for Celgene led to a huge quarter, but a drop in the deal count could give pause to those hoping for a bumper year.